Technical Analysis for ALNY - Alnylam Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
F 147.41 -1.25% -1.86
ALNY closed down 1.25 percent on Monday, March 18, 2024, on 50 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
180 Bearish Setup Bearish Swing Setup 0.00%
Multiple of Ten Bearish Other 0.00%
Gapped Up Strength 0.00%
Oversold Stochastic Weakness 0.00%
Multiple of Ten Bearish Other -1.25%
Outside Day Range Expansion -1.25%
Up 3 Days in a Row Strength -1.25%
Oversold Stochastic Weakness -1.25%
Oversold Stochastic Weakness -0.75%
Multiple of Ten Bearish Other -0.68%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakdown about 12 hours ago
Down 1% about 12 hours ago
10 DMA Support about 13 hours ago
Rose Above Previous Day's High about 13 hours ago
Up 1% about 13 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Alnylam Pharmaceuticals, Inc. Description

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). Its principal programs under clinical or pre-clinical development include ALN-TTR comprising ALN-TTR02 and ALN-TTRsc for the treatment of transthyretin-mediated amyloidosis; ALN-AT3 for the treatment of hemophilia and rare bleeding disorders; ALN-AS1 for the treatment of acute intermittent porphyria; ALN-PCS for the treatment of hypercholesterolemia; and ALN-TMP for the treatment of hemoglobinopathies, including beta-thalassemia. The company's early stage program comprise ALN-AAT, an RNAi therapeutic targeting the mutant Z-allele in alpha-1-antitrypsin deficiency (AAT deficiency) for the treatment of AAT deficiency-associated liver disease. It also has two partner-based programs in clinical development, including ALN-RSV01 for the treatment of respiratory syncytial virus infection; and ALN-VSP for the treatment of liver cancers, as well as one candidate in pre-clinical development comprising ALN-HTT for the treatment of Huntington's disease. The company has strategic alliances with F. Hoffmann-La Roche Ltd; Arrowhead Research Corporation; Takeda Pharmaceutical Company Limited; Monsanto Company; Isis Pharmaceuticals, Inc.; Novartis Pharma AG; Medtronic, Inc.; Kyowa Hakko Kirin Co., Ltd.; Genzyme Corporation; The Medicines Company; Cubist Pharmaceuticals, Inc; Biogen Idec Inc.; and Ascletis Pharmaceuticals (Hangzhou) Co., Ltd. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Clinical Development Cholesterol Liver Disease Amyloid Amyloidosis Hemoglobin Huntington's Disease Hemophilia Antitrypsin Deficiency Hypercholesterolemia Spinal Muscular Atrophy Genzyme Rna Interference Alnylam Pharmaceuticals Deficiency Hemophilia A Liver Cancer Thalassemia Therapeutic Gene Modulation Transthyretin Treatment Of Hemophilia Hemoglobinopathies Medtronic Acute Intermittent Porphyria Alpha 1 Antitrypsin Deficiency Beta Thalassemia Monsanto

Is ALNY a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 218.88
52 Week Low 143.52
Average Volume 922,953
200-Day Moving Average 179.05
50-Day Moving Average 168.01
20-Day Moving Average 151.99
10-Day Moving Average 148.83
Average True Range 4.84
RSI (14) 35.06
ADX 33.19
+DI 15.28
-DI 25.06
Chandelier Exit (Long, 3 ATRs) 149.50
Chandelier Exit (Short, 3 ATRs) 158.04
Upper Bollinger Bands 160.73
Lower Bollinger Band 143.26
Percent B (%b) 0.24
BandWidth 11.49
MACD Line -5.22
MACD Signal Line -5.85
MACD Histogram 0.6326
Fundamentals Value
Market Cap 18.5 Billion
Num Shares 125 Million
EPS -4.11
Price-to-Earnings (P/E) Ratio -35.87
Price-to-Sales 12.38
Price-to-Book 142.92
PEG Ratio -0.49
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 153.14
Resistance 3 (R3) 153.70 152.35 152.19
Resistance 2 (R2) 152.35 150.89 152.07 151.87
Resistance 1 (R1) 149.88 149.99 149.21 149.32 151.55
Pivot Point 148.53 148.53 148.19 148.25 148.53
Support 1 (S1) 146.06 147.07 145.39 145.50 143.27
Support 2 (S2) 144.71 146.17 144.43 142.95
Support 3 (S3) 142.24 144.71 142.64
Support 4 (S4) 141.68